Why the Global Push Against Nicotine Is Creating a New Category of Consumer Health Companies
Share
Around the world, governments, regulators, and public health organizations are no longer focused solely on reducing cigarette consumption. A broader shift is underway. The objective is increasingly clear: reduce nicotine dependence across all forms of delivery. This shift is not only reshaping public health policy, it is beginning to redefine an entire segment of the consumer health market.
For decades, tobacco control efforts primarily targeted combustible cigarettes. Public awareness campaigns, taxation policies, warning labels, and advertising restrictions all contributed to a gradual decline in smoking rates in many developed markets. Yet despite these efforts, the scale of the problem remains significant.
The Centers for Disease Control and Prevention states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.”¹ The same agency reports that cigarette smoking “kills more than 480,000 Americans each year.”² These figures underscore the ongoing impact of tobacco use on public health systems and national economies.
Globally, the numbers are even more substantial. According to the World Health Organization, tobacco use “kills more than 8 million people each year worldwide.”³ Despite decades of intervention, more than 1 billion people worldwide continue to smoke cigarettes.
At the same time, the nicotine landscape has evolved.
Electronic cigarettes and vaping devices have emerged as alternative nicotine delivery systems, gaining widespread adoption over the past decade. While some have positioned these products as alternatives to traditional smoking, regulators and health authorities continue to evaluate their long term impact.
The Centers for Disease Control and Prevention explains that “Most e-cigarettes contain nicotine,” and further notes that “Nicotine is highly addictive.”⁴ These realities have led to increasing scrutiny of products that continue to deliver nicotine, even in non combustible forms.
Youth exposure has become a central concern. The Centers for Disease Control and Prevention reports that “E-cigarettes are the most commonly used tobacco product among U.S. youth.”⁵ On a global scale, public health data cited by Reuters indicates that “At least 15 million children aged 13 to 15 are estimated to use e-cigarettes globally.”⁶
These trends are driving a broader regulatory response.
Governments are not only restricting traditional cigarettes, they are increasingly examining all forms of nicotine delivery. This includes tighter controls on vaping products, increased public education campaigns, and growing support for cessation programs that aim to eliminate nicotine use altogether.
Historically, major shifts in regulation have often led to the creation of entirely new industries. When environmental regulations increased, clean energy markets expanded. When automotive standards evolved, electric vehicle innovation accelerated. In each case, regulatory pressure did not eliminate demand. It redirected it.
A similar pattern may now be emerging in the nicotine sector.
As policymakers focus more directly on reducing nicotine dependence rather than simply changing how nicotine is delivered, a new category of consumer health products is beginning to take shape. This category is centered on solutions designed to help individuals transition away from nicotine entirely, rather than substituting one nicotine source for another.
For investors, this shift represents a structural change in the market.
The global smoking cessation industry already represents a multibillion dollar sector, supported by healthcare systems, insurers, and government initiatives. Yet traditional cessation tools have not fully solved the problem. Many individuals continue to struggle with relapse, and long term nicotine dependence remains widespread.
This creates space for innovation.
New approaches are emerging that aim to address both the behavioral and dependency aspects of smoking and vaping without introducing nicotine. These approaches reflect a growing alignment with regulatory priorities, which are increasingly focused on reducing overall nicotine exposure.
Within this evolving landscape, Redwood Scientific Technologies is developing nicotine free oral thin film technologies designed to align with these broader trends. Through its TBX FREE and TBX VAPE FREE platforms, the company is focused on creating solutions intended to address behavioral patterns associated with smoking and vaping while eliminating nicotine.
This positioning reflects a forward looking approach that is consistent with the direction of public health policy and regulatory focus. It does not represent a claim of clinical outcome, but rather an alignment with where the market and regulatory environment appear to be heading.
As regulatory pressure continues to increase and public awareness of nicotine dependence grows, the demand for new types of solutions may expand accordingly.
For investors and industry observers, the key question is not simply whether smoking rates will decline further. The more relevant question is how the broader nicotine ecosystem will evolve and which companies are positioned to operate within that future landscape.
The global push against nicotine is no longer a single issue. It is a multi dimensional transformation that is reshaping consumer behavior, regulatory frameworks, and market opportunities.
In that environment, new categories are formed.
And those categories often define the next generation of market leaders.
Sources and References
- Centers for Disease Control and Prevention
“Cigarette smoking remains the leading cause of preventable disease and death in the United States.”
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - Centers for Disease Control and Prevention
“Cigarette smoking kills more than 480,000 Americans each year.”
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - World Health Organization
“Tobacco kills more than 8 million people each year worldwide.”
https://www.who.int/news-room/fact-sheets/detail/tobacco - Centers for Disease Control and Prevention
“Most e-cigarettes contain nicotine.” / “Nicotine is highly addictive.”
https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html - Centers for Disease Control and Prevention
“E-cigarettes are the most commonly used tobacco product among U.S. youth.”
https://www.cdc.gov/tobacco/e-cigarettes/youth.html - Reuters citing World Health Organization data
“At least 15 million children aged 13 to 15 are estimated to use e-cigarettes globally.”
https://www.reuters.com/business/healthcare-pharmaceuticals/who-estimates-least-15-million-teenagers-use-e-cigarettes-worldwide-2025-10-06/
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.